Insitro is a Biotechnology founded in 2018, currently valued at $2B. IPO Status: Pre-IPO (monitoring). IPO Readiness Score: 65/100 (C+).
Insitro IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | Biotechnology |
| Stage | Series D |
| IPO Status | Private |
| Valuation | $2B |
| Total Funding | $993M |
| Headquarters | South San Francisco, CA |
| IPO Readiness Score | 65/100 |
| Founded | 2018 |
Track Insitro IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
Machine learning-driven drug discovery company using large-scale data generation and AI to identify new therapeutics.
Insitro is currently a private company being monitored by TechStackIPO for potential IPO activity. The company’s IPO readiness score is 65/100. Companies in the Biotechnology sector have seen significant IPO activity in recent years, with several notable listings and S-1 filings tracked on TechStackIPO. Key factors that could accelerate Insitro’s path to IPO include revenue growth, profitability milestones, favorable market conditions, and strategic investor interest.
Insitro is valued at $2B based on the most recent private market data. The company has raised a total of $993M in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Accredited investors may be able to access Insitro pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Insitro has an IPO readiness score of 65/100 on TechStackIPO. A moderate readiness score suggests the company may be 2–4 years from IPO.
Insitro's last known private valuation is $2B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. Insitro has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
Insitro operates in the Biotechnology sector. TechStackIPO tracks multiple Biotechnology companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Insitro against other Biotechnology companies using TechStackIPO's comparison tool.
Insitro is at the Series D stage. The company has raised a total of $993M in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Insitro is headquartered in South San Francisco, CA. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.